Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02899000 · ClinicalTrials.gov registry record · Phase 4
A Treatment for Severe Inflammatory Acne Subjects
A Phase 4 study of Acne Vulgaris, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 186
- Enrollment target
- 1
- Study location
NCT02899000: Completed Phase 4 study of Acne Vulgaris, sponsored by Galderma R&D.
NCT02899000 is a Phase 4 study of Acne Vulgaris that has completed, run by Galderma R&D. The registered enrollment target is 186 participants, below the 273-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (32% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02899000, a Phase 4 study of Acne Vulgaris, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 186 participants
- Enrollment target
- 1
- Study location
Study Summary
Demonstrate that a daily treatment regimen of adapalene 0.3%/benzoyl peroxide 2.5% gel + oral Doxycycline 200 mg is effective and safe in severe inflammatory acne with 3 or fewer nodules or cysts (non-nodulocystic) during a 12-week treatment period.
Primary Outcome
Change in Number of Inflammatory Lesions from baseline.
Conditions Studied
Interventions
- DRUG Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel
- DRUG Oral doxycycline hyclate
Study Locations (1)
Texas
- Galderma Laboratories, LP - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2016-07-29 |
| Est. Completion | 2017-06-27 |
| Phase | Phase 4 |
What the finished NCT02899000 record still lists
NCT02899000 is an interventional study that assigns participants to a tested intervention. The registered 186 participants enrollment target is mid-sized for trials with a published cap, below the 273-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (32% lower).
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 2 interventions - of which Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel is the first listed.
NCT02899000 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02899000 about?
NCT02899000 is a clinical study titled "A Treatment for Severe Inflammatory Acne Subjects". Demonstrate that a daily treatment regimen of adapalene 0.3%/benzoyl peroxide 2.5% gel + oral Doxycycline 200 mg is effective and safe in severe inflammatory acne with 3 or fewer nodules or cysts (non-nodulocystic) during a 12-week treatment period.
What is the current status of trial NCT02899000?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 186 participants. The study started on 2016-07-29. Estimated completion is 2017-06-27.
What conditions does trial NCT02899000 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT02899000?
The interventions under investigation include: Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel (DRUG), Oral doxycycline hyclate (DRUG).
Who is sponsoring clinical trial NCT02899000?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02899000 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02899000's enrollment target sits among peer trials
186 29th of 67 higher than 38 of 67 other Acne Vulgaris trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acne Vulgaris trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients
ACTIVE NOT RECRUITING · Phase 4
-
Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris
COMPLETED · Phase 4
-
AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation
COMPLETED · Phase 4
-
A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)
COMPLETED · Phase 4
-
Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%
COMPLETED · Phase 4
-
Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03567889 · 186 participants · Phase 3
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- NCT05281471 · 186 participants · Phase 3
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- NCT05405595 · 186 participants · Phase 1
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- NCT05762107 · 186 participants · Phase 2
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI